How to buy Agios Pharmaceuticals stock | 35.28

Agios Pharmaceuticals, Inc is a biotechnology business based in the US. Agios Pharmaceuticals shares (AGIO) are listed on the NASDAQ and all prices are listed in US Dollars. Agios Pharmaceuticals employs 536 staff and has a trailing 12-month revenue of around USD$185.9 million.

How to buy shares in Agios Pharmaceuticals

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Agios Pharmaceuticals. Find the stock by name or ticker symbol: AGIO. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Agios Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$35.28, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Agios Pharmaceuticals, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Agios Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Agios Pharmaceuticals's share price?

Since the stock market crash in March caused by coronavirus, Agios Pharmaceuticals's share price has had significant negative movement.

Its last market close was USD$35.28, which is 33.57% down on its pre-crash value of USD$53.11 and 27.03% up on the lowest point reached during the March crash when the shares fell as low as USD$27.774.

If you had bought USD$1,000 worth of Agios Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$686.25 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$711.24.

Agios Pharmaceuticals share price

Use our graph to track the performance of AGIO stocks over time.

Agios Pharmaceuticals shares at a glance

• Key figures

Information last updated 2020-10-14.

Latest market close	USD$35.28
52-week range	USD$27.774 - USD$56.75
50-day moving average	USD$37.3434
200-day moving average	USD$44.2942
Wall St. target price	USD$65.17
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-6.673

Buy Agios Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Agios Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Agios Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Agios Pharmaceuticals price performance over time

Historical closes compared with the close of $35.28 from 2020-10-19

1 week (2020-11-19)	-15.58%
1 month (2020-10-26)	-5.87%
3 months (2020-08-26)	-8.67%
6 months (2020-05-26)	-32.74%

1 year (2019-11-26)	-5.42%
2 years (2018-11-26)	-47.30%
3 years (2017-11-24)	-42.41%
5 years (2015-11-25)	-48.51%

Agios Pharmaceuticals financials

Revenue TTM	USD$185.9 million
Gross profit TTM	USD$-294,299,000
Return on assets TTM	-24.74%
Return on equity TTM	-62.18%
Profit margin	-182.49%
Book value	$8.087
Market capitalisation	USD$2.5 billion

TTM: trailing 12 months

Shorting Agios Pharmaceuticals shares

There are currently 6.9 million Agios Pharmaceuticals shares held short by investors – that's known as Agios Pharmaceuticals's "short interest". This figure is 14.6% up from 6.0 million last month.

There are a few different ways that this level of interest in shorting Agios Pharmaceuticals shares can be evaluated.

Agios Pharmaceuticals's "short interest ratio" (SIR)

Agios Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Agios Pharmaceuticals shares currently shorted divided by the average quantity of Agios Pharmaceuticals shares traded daily (recently around 604815.19650655). Agios Pharmaceuticals's SIR currently stands at 11.45. In other words for every 100,000 Agios Pharmaceuticals shares traded daily on the market, roughly 11450 shares are currently held short.

However Agios Pharmaceuticals's short interest can also be evaluated against the total number of Agios Pharmaceuticals shares, or, against the total number of tradable Agios Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Agios Pharmaceuticals's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Agios Pharmaceuticals shares in existence, roughly 100 shares are currently held short) or 0.1552% of the tradable shares (for every 100,000 tradable Agios Pharmaceuticals shares, roughly 155 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Agios Pharmaceuticals.

Find out more about how you can short Agios Pharmaceuticals stock.

Agios Pharmaceuticals share dividends

We're not expecting Agios Pharmaceuticals to pay a dividend over the next 12 months.

Agios Pharmaceuticals share price volatility

Over the last 12 months, Agios Pharmaceuticals's shares have ranged in value from as little as $27.774 up to $56.75. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Agios Pharmaceuticals's is 1.8439. This would suggest that Agios Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Agios Pharmaceuticals overview

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted cancers; and AG-636 that is in pre-clinical stage for treating hematologic malignancies. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.

Frequently asked questions

• What percentage of Agios Pharmaceuticals is owned by insiders or institutions?

  Currently 11.369% of Agios Pharmaceuticals shares are held by insiders and 102.1% by institutions.

• How many people work for Agios Pharmaceuticals?

  Latest data suggests 536 work at Agios Pharmaceuticals.

• When does the fiscal year end for Agios Pharmaceuticals?

  Agios Pharmaceuticals's fiscal year ends in December.

• Where is Agios Pharmaceuticals based?

  Agios Pharmaceuticals's address is: 88 Sidney Street, Cambridge, MA, United States, 02139

• What is Agios Pharmaceuticals's ISIN number?

  Agios Pharmaceuticals's international securities identification number is: US00847X1046

• What is Agios Pharmaceuticals's CUSIP number?

  Agios Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 00847X104